ArticleFrontiers in oncology2026
cGAS/STING-mediated upregulation of NKG2D ligands in LSCs contributes to enhanced sensitivity to NK cells.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Natural killer (NK) cells-mediated immune surveillance is essential role for tumor recognition and elimination. The binding of NK group 2 member D (NKG2D) ligands to NKG2D receptor is sufficient to activate the NK cells' cytotoxicity against targeted cells. Here we reported that the inhibition of poly (ADP-ribose) polymerase 1 (PARP1) in leukemia stem cells (LSCs) induced the expression of NKG2D ligands through the activation of DNA damage response. Methods: Flow cytometry and Quantitative real-time RT-PCR were used to detect the expression levels of NKG2D ligands on cell surface and mRNA levels in leukemia cells, respectively. Cytotoxicity assay was applied to examine the cytotoxic activity of NK cells against leukemia cells. Dual luciferase reporter (DLR) assay was employed to detect the promoter activation of NKG2D ligands. Western blotting was conducted to check the protein expression level. Results: Activated ataxia-telangiectasia mutated proteins (ATM) and ɣH2AX foci accumulation were observed under the treatment of PARP inhibitor, leading to the accumulation of damaged DNA. Subsequently, cyclic GMP-AMP synthase (cGAS) was activated, and stimulator of interferon gene (STING) was recruited to promote the downstream signal transduction via TANK-binding kinase-1 (TBK1) and transcription regulatory factor 3 (IRF3). However, the NKG2D ligands induced by PARP inhibitor was reduced in STING or IRF3-knockdown LSCs, indicating that STING and IRF3 were necessary for the regulation of NGK2D ligands in LSCs upon the DNA damage response. Discussion: These data indicated that the DNA damage response-mediated cGAS/STING/TBK1/IRF3 signalling pathway played an essential role in modulating NKG2D ligands expression in LSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.